Conclusion: Rasagiline is an investigational selective and irreversible inhibitor of MAO-B that has demonstrated efficacy and safety for the treatment of PD. Whether rasagiline is associated with ...

Announcing a new publication for Acta Materia Medica journal. Monoamine oxidase (MAO) is a useful target in the treatment of neurodegenerative diseases and depressive disorders. Understanding the ...

Healthcare providers may prescribe levodopa, dopamine agonists, anticholinergics, catechol-o-methyltransferase (COMT) inhibitors, and type-B monoamine oxidase (MAO-B) inhibitors to manage symptoms.

Understanding the structure-activity relationship (SAR) and mechanisms underlying MAO inhibitors is crucial but ... significantly enhanced MAO-B inhibition and increased selectivity for MAO ...

For example, based on a Parkinson's disease rating scale for motor symptoms, those on MAO-B inhibitors who then received placebo infusions scored 6.82 at the end of the year, while those taking ...